J Frontier Co.,Ltd. risk profile
23 Normal where most of the sector sits
Measured 1 September 2026 from R0L's filed statements. Recomputed nightly.
23 (Normal), driven by Market expectation at 75, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 75 | Stretched | Stable | Drawdown from the 52-week high — 43.5% |
| Operating pressure | 36 | Normal | Worsening | Operating-margin drift — -4.8 percentage points |
| Cash conversion | 25 | Normal | Easing | Free-cash-flow margin — 2.1% |
| Leverage and coverage | 31 | Normal | Easing | Net debt to EBITDA — 2.38x |
| Competitive position | 2 | Contained | Stable | Revenue-growth gap against peers — +66.0 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for J Frontier Co.,Ltd.